Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond. A look at the numbers
Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55
Read More
Eli Lilly and Co
These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
Piper Sandler analyst Allison Bratzel said the loss of lean muscle while taking GLP-1 drugs is "a major shortcoming" that
Read More
‘Miracle drug’ euphoria: Experts warn widespread use of weight loss medicine faces major hurdles
Two experts see major challenges facing the adoption of Novo Nordisk and Eli Lilly's obesity drugs. Source link
Read More
Many are betting Ozempic will reduce the need for knee surgery. What it means if they’re wrong
Investors are making a lot of bets about GLP-1 drugs, but what if those hunches are incorrect? Source link
Read More
Which stocks might be disrupted next by Ozempic and other GLP-1 drugs
GLP-1 medications could have far-reaching implications for a wide variety of conditions, from liver disease to sleep apnea to heart
Read More
Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data
Structure's pill is part of the same class of drugs as Novo Nordisk's blockbuster diabetes drug Ozempic and weight loss
Read More
Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years
The data confirms the rise in demand for GLP-1s, which have fueled a frenzy among Americans and on Wall Street
Read More
Stocks making the biggest moves midday: Splunk, Cisco, Broadcom, Fox and more
These are the stocks posting the largest moves in midday trading. Source link
Read More
Jefferies upgrades Eli Lilly as enthusiasm around weight-loss drugs grows following Wegovy study
Eli Lilly stock will continue to benefit from a strong second quarter thanks to the success of obesity drugs, according
Read More